Disease · MONDO_0003005
Comparisons in its trials61
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 61
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aflibercept vs Bevacizumab: deaths from any cause | 1 of 180 | 1 of 182 | 362 | NCT01969708 | Trial comparisons |
| Aflibercept vs Bevacizumab: serious adverse events | 14 of 180 | 14 of 182 | 362 | NCT01969708 | Trial comparisons |
| 700 μg Dexamethasone vs Sham: serious adverse events | 1 of 129 | 2 of 130 | 259 | NCT01660802 | Trial comparisons |
| Ranibizumab vs Dexamethasone: Rate of the Internal Ocular Pressure (IOP) | 79 of 126 | 106 of 118 | 244 | NCT01396057 | Trial comparisons |
| Ranibizumab vs Dexamethasone: serious adverse events | 7 of 126 | 9 of 118 | 244 | NCT01396057 | Trial comparisons |
| Ranibizumab vs Dexamethasone: Increase Rate of the Internal Ocular Pressure (IOP ) : Patients With ≥10% Increase in IOP Compared to Baseline | 94 of 124 | 105 of 119 | 243 | NCT01396083 | Trial comparisons |
| Ranibizumab vs Dexamethasone: serious adverse events | 10 of 124 | 16 of 119 | 243 | NCT01396083 | Trial comparisons |
| Macular Laser Photocoagulation Treatment (Control) vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321): serious adverse events | 10 of 92 | 13 of 91 | 183 | NCT01521559 | Trial comparisons |
Macular Laser Photocoagulation Treatment (Control) vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321): Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF | 24 of 90 | 48 of 91 | 181 | NCT01521559 | Trial comparisons |
| Ranibizumab vs Sham With Ranibizumab: Number of Participants Requiring Rescue Treatment at Month 1 | 0 of 117 | 0 of 60 | 177 | NCT01846299 | Trial comparisons |
| Ranibizumab vs Sham With Ranibizumab: Number of Participants With Presence of Active Macular Edema (ME) Leakage | 96 of 117 | 53 of 60 | 177 | NCT01846299 | Trial comparisons |
| 4mg CLS-TA Suprachoriodal Injection vs Sham Procedure: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks | 45 of 96 | 10 of 64 | 160 | NCT02595398 | Trial comparisons |
| 4mg CLS-TA Suprachoriodal Injection vs Sham Procedure: deaths from any cause | 0 of 96 | 0 of 64 | 160 | NCT02595398 | Trial comparisons |
| 4mg CLS-TA Suprachoriodal Injection vs Sham Procedure: serious adverse events | 3 of 96 | 0 of 64 | 160 | NCT02595398 | Trial comparisons |
| BRVO vs CRVO: serious adverse events | 17 of 42 | 12 of 39 | 81 | NCT01003106 | Trial comparisons |
| Updated DEX PS DDS 0.7 mg vs Approved DEX PS DDS 0.7 mg: Number of Participants Experiencing at Least One Adverse Events (AEs) | 13 of 36 | 7 of 18 | 54 | NCT04976777 | Trial comparisons |
| Updated DEX PS DDS 0.7 mg vs Approved DEX PS DDS 0.7 mg: deaths from any cause | 0 of 36 | 0 of 18 | 54 | NCT04976777 | Trial comparisons |
| Updated DEX PS DDS 0.7 mg vs Approved DEX PS DDS 0.7 mg: serious adverse events | 1 of 36 | 0 of 18 | 54 | NCT04976777 | Trial comparisons |
| Dorzolamide-timolol vs Artificial Tears: deaths from any cause | 0 of 27 | 0 of 25 | 52 | NCT03034772 | Trial comparisons |
| Dorzolamide-timolol vs Artificial Tears: serious adverse events | 0 of 27 | 0 of 25 | 52 | NCT03034772 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003005/comparisons